Ken Griffin Poseida Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$2.0 - $3.46 $83,400 - $144,282	41,700 Added 44.84%	134,700 $393,000
Q1 2024 May 15, 2024	BUY	$2.76 - $4.13 $256,679 - $384,090	93,000 New	93,000 $296,000
Q3 2023 Nov 14, 2023	SELL	$1.62 - $2.79 $43,254 - $74,493	-26,700 Reduced 55.74%	21,200 $50,000
Q2 2023 Aug 14, 2023	BUY	$1.66 - $3.4 $16,932 - $34,680	10,200 Added 27.06%	47,900 $84,000
Q1 2023 May 15, 2023	BUY	$3.08 - $8.73 $37,884 - $107,379	12,300 Added 48.43%	37,700 $116,000
Q4 2022 Feb 14, 2023	BUY	$3.33 - $6.38 $26,640 - $51,040	8,000 Added 45.98%	25,400 $134,000
Q3 2022 Nov 14, 2022	BUY	$2.43 - $4.51 $42,282 - $78,474	17,400 New	17,400 $61,000

38.3M

417K

42.7K

Ticker PSTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,775,600
Market Cap $318M
Description
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.